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Lack of major metabolic perturbations in the hippocampus of 4.5-month-old APP/PS1 mice
5 of the 98 selected metabolites were found to significantly discriminate between PBS-treated WT and APP/PS1 mice (Table1), albeit predominantly in females. Levels of L-beta-aspartyl-L-glutamic acid, which belongs to the family of N-acyl-alpha amino acids and derivatives which are known for their antiinflammatory action (1), were particularly reduced in female APP/PS1 mice (Suppl. Fig. 2A ), but its function and implication in AD pathology is, to the best of our knowledge, unknown. 1-Methyladenosine, an oxidized nucleoside known to be immunosuppressive on macrophage function (2) and found in elevated levels in the urine of patients with mild-to-moderate AD (3), was more abundant in the hippocampus of female APP/PS1 mice compared to their WT female littermates (Suppl. Fig. 2B ).
Significant Genotype X Treatment interactions were also found for N-acetyl-(L)-arginine (F(1,34)=12.07, p=0.001), whose levels were significantly lower in PBS-treated APP/PS1 females compared to PBS-treated WT females (Suppl. Fig. 2C ), and for the hydrophobic tetrapeptide Asp-Phe-Thr-Thr (F(1,34)=5.40, p=0.03), whose levels were significantly increased in PBS-treated APP/PS1 males compared to their PBS-treated counterparts (Suppl. Fig. 2D ). Their function and potential roles in AD pathology are also, to the best of our knowledge, unknown.
Sex differences in the hippocampal metabolic profile are independent of the APP/PS1 genotype.
Forty-one metabolites with sex differences were identified revealing major changes in amino acids, carbohydrate metabolism and fatty acyls (Table 1) . A few metabolites from other chemical classes and many unknown metabolites were also found in different levels between PBS-treated males and females (Table 1 ). Metabolic differences in the methionine and pyruvate metabolic pathways are described in the main manuscript and illustrated Fig. 5 and 6 , respectively. Changes in other metabolites with previously associated with differences immune function are described below. Their potential role in brain function or implication in AD progression is presented in Suppl. Table 3 .
These included reduced levels of (3R)-beta leucine (Suppl. Fig. 3 ), a degradation product of the anti-inflammatory amino acid L-Leucine (4), D-alanyl-D-alanine (Suppl. Fig. 3B ), an anti-inflammatory antibiotic-binding protein (5) , and N(pi)-methyl-L-histidine (Suppl. Fig. 3C ), a metabolic product of the amino acid histidine known to be negatively associated with inflammation in obese women (6) . Females also presented with an increased abundance of N-Succinyl-L-glutamate 5-semialdehyde (Suppl. Fig. 3D ), a metabolite found to be elevated in the plasma of lung cancer patients harbouring a mutation in the epidermal growth factor receptor (7) that also exacerbate their pro-inflammatory status (8) .
Lysine, whose dietary restriction was found to trigger pro-inflammatory changes (9), indicated the major anti-inflammatory pathway upregulated in females as seen by elevated levels in three metabolites involved in lysine biosynthesis :N6-(L-1,3-Dicarboxypropyl)-L-lysine, N2-Acetyl-L-aminoadipate and L-2-Aminoadipate (Suppl. Fig. 3E-G) , and reduced levels of L-pipecolate (Suppl. Fig. 3H ), a degradation product of L-lysine whose urine levels are positively associated with low grade inflammation (10) .
Differences in amino acid metabolism also indicative of anti-inflammatory effects in females included increased abundance of pantothenate (vitamin B5; Suppl. Fig. 3I ), whose dietary intake was found to alleviate chronic low grade inflammation (11) and norepinephrinesulfate (Suppl. Fig. 3O ), a metabolite of the anti-inflammatory neurotransmitter norepinephrine (12) , as well as reduced levels of (Z)-4-Hydroxyphenylacetaldehyde-oxime (Suppl. Fig. 3J ), an enzyme involved in tyrosine metabolism found in increased levels in inflammatory bowel disease (13) , and homoarginine (Suppl. Fig. 3K ), known to be negatively associated with pro-inflammatory changes (14) .
Changes in carbohydrate metabolism and fatty acyls seen in females were indicative of a proinflammatory status. Furthermore, isocitrate, a substrate of the tricarboxylic acid (TCA) cycle found to exert anti-inflammatory effects in a rat model of mild anemia of inflammation (15) and itaconate, a potent anti-inflammatory TCA derivative found in immune cells (16) , were also less abundant in the female hippocampus (Suppl. Fig. 3M&N , respectively). Hippocampal concentrations of formyl 3-hydroxybutanoate, a fatty ester, were also significantly lower in females (Suppl. Fig. 3L ) and fatty esters are thought to be anti-inflammatory (17) .
Metabolites differentially expressed in PBS-and LPS-treated mice regardless of sex and genotype.
Thirty six metabolites were altered to similar extents by LPS in all experimental groups ( Table 1 ).
The most significant changes were those affecting tryptophan and methionine metabolism, as described in the main manuscript and represented Figs. 4&5, respectively. Changes to other metabolites associated with immune status are described below and represented Suppl. Fig. 4 , and the potential association of these metabolites in brain function, sex differences and/or AD progression is described in Suppl. Table 3 .
These metabolic differences included increased levels of thymidine and thymine (Suppl. Fig. 4A&B ), two derivatives of the anti-inflammatory nucleotide pyrimidine (18) as well as reduced levels of the inflammation signalling molecule adenosine triphosphate (ATP) (19) , particularly in WT mice (Suppl. Fig.   4C ) and of succinate (Suppl. Fig. 4D ), a pro-inflammatory intermediate of the TCA cycle which plays a crucial role in ATP generation (20) .
Pro-inflammatory metabolic changes included increased levels of N(pi)-methyl-L-histidine (Suppl. Fig. 4C ), an histidine derivative positively associated with levels of pro-inflammatory markers (21), urate (Suppl. Fig. 4E ) known to cause cognitive deficits through enhancing hippocampal inflammation (22) , and of its downstream metabolite urea-1-carboxylate (Suppl. Fig. 4F ). LPS-treated mice also had elevated hippocampal levels of L-phenylalanine (Suppl. Fig. 4G ), whose circulating levels are increased in elderly people with chronic low grade inflammation (23) and prostaglandin-H2-ethanolamide (PGH2-EA) (Suppl. Fig. 4H ), a precursor of prostaglandin E2 (PGE2), which plays a major role in acute inflammation and transition to chronic inflammation (24) , and is a key mediator of LPS-induced sickness (25) .
Metabolites sex-dependently affected by LPS
Forty-six metabolites showed sex-dependent effects of LPS, of which twenty-one were selectively altered in males, twenty were selectively altered in females, and five showed opposite effects in the two sexes (Table 1 ). These changes particularly affected two metabolic pathways: pyruvate ( Fig. 6 ) and methylglyoxal ( Fig. 8 ). Changes in other metabolites known to be associated with immunomodulation are reported below and illustrated Suppl. Fig. 4 .
Metabolic effects of LPS in males
Levels of methylimidazoleacetic acid (Sex X Treatment: F(1,34)=13.22, p=0.0009, Suppl. Fig. 4J ), a metabolite of the pro-inflammatory mediator histamine (26) were increased by LPS in APP/PS1 males.
Other metabolic changes found in LPS-treated males include increased levels of norepinephrinesulfate (Sex X Treatment: F(1,34)=6.64, p=0.01, Suppl. Fig. 3O ), a metabolite of the antiinflammatory neurotransmitter norepinephrine (12) , choline (Sex X Treatment: F(1,34)=19.89, p<0.0001, Suppl. Fig. 4K ), a precursor of acetylcholine and agonist of α7 nicotinic receptors expressed in neurons and macrophages with established anti-inflammatory effects (27, 28) , found to dose-dependently inhibit LPS-induced TNFa production by macrophages (29) , L-rhamnose (Sex X Treatment: F(1,34)=7.25, p=0.01, Suppl. Fig. 4L ), previously shown able to inhibit pro-inflammatory cytokines production (30) , and hypoxantine (Sex X Treatment: F(1,34)=10.06, p=0.003, Suppl. Fig. 4M ), whose levels are negatively correlated with the severity of mucosal inflammation (31) .
Metabolic effects of LPS in females
6-Phospho-D-gluconate (Suppl. Fig. 4N ), an intermediate of the pentose phosphate pathway known to trigger pro-inflammatory cytokines secretion in LPS-activated macrophages (32), was less abundant in LPS-treated females Pro-inflammatory metabolic changes found in LPS-treated females include reduced levels of N2-Succinyl-L-ornithine (Sex X Treatment: F(1,34)=6.25, p=0.02, Suppl. Fig. 4N ), a degradation product of the anti-inflammatory amino acid arginine (33) , and, in WT LPS-treated females, and homoarginine (Suppl. Fig. 3K ), known to be negatively associated with pro-inflammatory changes (14) .
Metabolites showing opposite pattern in LPS-treated males and females
Two of the five metabolites that showed opposite effects of LPS in males and females, S-Adenosy-L-homocysteine Fig. 4E ) and N-Succinyl-L-glutamate 5-semialdehyde (Suppl. Fig. 3D ), have been reported to be associated with increased inflammation. They both were found more abundant in male hippocampi but less abundant in female hippocampi 4 hours after LPS administration.
Suppl. Table 3 . Physiological role of metabolites from known metabolic pathways differently expressed between PBS-treated WT and APP/PS1 mice, PBS-treated males and females and in response to LPS.
Putative metabolite Metabolic Pathway Physiological role in the brain Implication in sex differences in brain function
Implication in Alzheimer's disease (AD) Implication in immune status
Amino acid metabolism
Valine, leucine and isoleucine degradation
Degradation product of L-Leucine which is produced by muscle protein catabolism and serves as a donor for brain glutamate synthesis by astrocytes and cerebral protein synthesis (34) .
Not known
Increased serum levels of l-leucine in AD patients and in the 3xTg mouse model of AD (35) .
L-leucine up-regulates tau phosphorylation in 3xTg mice (35) .
L-leucine reduces inflammation and increases repair after muscle injury in rats (4).
Choline
Glycine, serine and threonine metabolism
Precursor for the cerebral synthesis of acetylcholine, a neurotransmitter essential for cognitive function, and phospholipid phosphatidylcholine, a major constituent of biological membranes in neurons and glial cells (36, 37) .
Higher choline concentrations in the hippocampus of cognitively intact elderly females (38) .
Loss of cholinergic function in AD is associated with memory decline (39) .
Dietary intake of choline improves cognitive function in AD patients and mouse models (37) .
Agonist of α7 nicotinic receptors expressed on macrophages, supresses LPS-induced TNFa production by macrophages (29) .
L-cystathionine
Methionine metabolism
Intermediate in the transsulfuration pathway which decreases neurotoxic homocysteine concentrations (40) Mediates the conversion of homocysteine into cysteine (Fig. 5 ).
Not known
Increased levels in the temporal cortex of post-mortem AD brains (41) .
Inhibits the expression of the proinflammatory cytokine MCP-1 in macrophages in vitro (42) .
L-methionine Methionine metabolism
Key role in epigenetic regulation in the brain through conversion into homocysteine via S-adenosyl-Lmethionine (43) .
No differences in mouse brain concentrations (44) .
Decreased levels in the temporal cortex of post-mortem AD brains (41) .
Elevated CSF levels in MCI and AD (45) .
Excess dietary methionine induces cognitive and neurological hallmarks of AD in mice (46) . Excess dietary methionine induces astrocyte and microglia activation in the hippocampus (46) .
Induces pro-inflammatory activation in macrophages in vitro (47) .
L-methionine S-oxide Methionine metabolism
Toxic oxidation product of methionine (48) . Not known Increased production triggers Aβ aggregation (49).
Inhibition reduces TNFa and IL1β secretion in LPS-stimulated microglia (50).
S-adenosyl-Lhomocysteine
Methionine metabolism
Biosynthetic precursor of homocysteine (Fig. 5) which is neurotoxic and pro-inflammatory in microglia (51) .
Formed by demethylation of Sadenosyl-L-methionine.
Increased levels in the postmortem AD brain are associated with cognitive dysfunction and neurological hallmarks of AD (52) .
Increase Aβ formation in BV-2 microglial cells (53) .
Induces pro-inflammatory activation in endothelial cells in vitro (54) .
O-succinyl-L-homoserine Methionine metabolism
Mediates the conversion of homocysteine into cystathionine (Fig. 5) .
Not known Not known Not known S-adenosyl-Lmethionine
Arginine and proline metabolism Main donor of methyl groups for DNA methylation in the brain (43) .
Dietary supplementation improves cognitive abilities in mice (55) .
Decreased levels in the postmortem AD brain (56) and CSF of AD patients (57) .
Inhibits TNFa production and enhances IL-6 and IL-10 secretion in LPS-stimulated human macrophages and/or murine monocytes (58, 59).
5'-methylthioadenosine
Arginine and proline metabolism Neuro-protective and antiinflammatory derivative of methionine.
Not known Increased CSF levels in MCI impaired patients (60) .
Reduces brain damage; inhibits
INFg and TNFa production and enhances IL-10 production in animal models of neuroinflammation (61 Improves mood and cognition by enhancing serotoninergic neurotransmission (70) and nicotinamide pathway (71) Women are more susceptible to episodic memory impairment caused by acute tryptophan depletion (72) .
Lower plasma tryptophan levels in females associated with reduced serotonin synthesis rate throughout the brain (73) .
Reduced CSF levels in MCI, but not AD, patients (60) .
Reduced serotoninergic neurotransmission associated with the development of cognitive symptoms in AD (74) .
Upregulation of kynurenine pathway associated with neurological hallmarks of AD (75) .
Increases inflammation via stimulation of the kynurenine pathway (76) .
Serotoninergic neurotransmission thought to protect against neuroinflammation (77).
5-hydroxyindoleacetate Tryptophan metabolism
End metabolite of the serotonin pathway of tryptophan metabolism (Fig. 6 ).
See L-tryptophan Elevated CSF levels in MCI and AD (45) . 
Glutathione disulphide (GSSG)
Glutamate metabolism
Glutathione metabolism
Toxic oxidation product of the antioxidant glutathione produced and exported by astrocytes in the brain (79) .
No sex differences in brain tissue content with aging in mice despite the most pronounced decline in glutathione concentrations seen in males (80).
Higher activity of glutathione reductase activity, which catalyses the reduction of GSSG disulphide in glutathione, in the temporal cortex of AD patients (81), but unaltered GSSG contents (82) .
Increased circulating levels during acute systemic inflammation in the rats (83) .
Methylimidazoleacetic acid Histidine metabolism
Main metabolite of histamine, a neuromodulator, also involved in cognition, wakefulness and anxiety and motivated behaviours (84, 85) .
Not known
Degeneration of histaminergic nerve fibres in AD (86).
Histamine is produced by immune cells in the brain, induces proinflammatory microglial activation but inhibits LPS-induced microglial activation (87) .
N(pi)-methyl-L-histidine Histidine metabolism
Derivative of histidine, a precursor of brain histamine (85) .
Not known Not known
Serum histidine levels are negatively associated with systemic inflammation (C-reactive protein levels) in obese women (6) . Ameliorates metabolic deficits of glial cells with mitochondrial dysfunction (92) .
Not known
Reduced whole brain content from 9 months of age in an APP/PS1 mouse model (93) .
Pro-inflammatory mediator in macrophages mediating LPSinduced IL-1β production (20, 94) .
Isocitrate
Citrate cycle (TCA cycle)
Glyoxylate and dicarboxylate metabolism
Not known Not known
Increased CSF levels in a transgenic rat model of tauopathy (95) .
Anti-inflammatory in rat model of anaemia of inflammation (15) .
Microglial deficiency in isocitrate dehydrogenase, the enzyme that catalyses oxidative decarboxylation of isocitrate, suppresses LP-induced pro-inflammatory cytokine production (TNFa, IL-6, IL-1β) 
D-sorbitol
Fructose and mannose metabolism Intermediate in the production of fructose from glucose in the brain (120) .
Not known Elevated levels in the post-mortem AD brain (121) .
Anti-inflammatory properties in resident cells from articular cartilage (122).
6-phospho-D-gluconate Pentose phosphate pathway
Regulatory control of brain metabolism (123) .
Not known
Increased activity of the pentose phosphate pathway associated with increased pro-oxidant activity in the post mortem AD brain (124) Triggers pro-inflammatory cytokines secretion in LPSactivated macrophages (32 Hypoxanthine is anti-inflammatory and depleted in LPS-stimulated macrophages (127) .
Urate
Purine metabolism Neuroprotective and antioxidant at physiological levels (128) .
Reduced brain tissue contents in women (129).
Increased CSF contents in AD (130) .
Trends towards reduced levels in the post-mortem AD brain (129) .
High uric acid diet causes cognitive deficits by inducing hippocampal neuroinflammation (22) .
Suppresses LPS-induced proinflammatory microglial activation in vitro (131). 
Fatty acids biosynthesis
Biosynthesis of unsaturated fatty acids
Needed for the synthesis of membranes of neurons and astrocytes during brain development (132) .
No sex differences in mouse brain content with normal diet (133) .
Induces tau phosphorylation in cultured neurons and astrocytes (134) .
Triggers secretion of Aβ peptide (135).
Reduced levels in the post-mortem AD brain (136) .
Accumulates primarily in astrocytes (137) where it triggers the release of TNFα and IL-6 (138).
Hexadecanoic acid (16:0 palmitic acid)
Biosynthesis of unsaturated fatty acids
Dietary administration, which enters the brain, improves cognitive and motor function (139) .
Induces tau phosphorylation and amyloid processing in cultured neurons and astrocytes (134, 135, 140) .
Increased levels in the postmortem AD brain (136) .
Triggers astrocytic release of TNFα and IL-6 in vitro (138) .
Impairs the protective migratory and phagocytic activities of microglia in both males and females (141) . No sex differences in mouse brain content with normal diet (133) .
Triggers secretion of Aβ peptide (135) .
Reduced levels in the post-mortem AD brain (136, 144) .
Precursor of potent proinflammatory eicosanoids (e.g. prostaglandins) in astrocytes (145) .
Does not trigger pro-inflammatory cytokine release in astrocytes (138).
PGH2-EA Eicosanoids
Metabolite of the endocannabinoid anandamide known to modulate the brain reward system (146) Not known Increases the neurotoxicity of Aβ peptide (147).
Precursor of prostaglandin E2 which mediates LPS-induced sickness (148) . Greater ATP production in female mitochondria in the rodent brain (107) Decreased brain contents in a transgenic rat model of tauopathy (95) and mouse model of amyloidosis (151).
Pro-inflammatory signalling molecule in the brain via increased synthesis of prostaglandin E2 (19) .
Produced by microglia and astrocytes, leading to microglial activation and chemotactic factor for microglia towards tissue injury (152, 153) Supplementary. Fig. 2 . Metabolites affected in APP/PS1 mice in the absence of immune stimulation. Levels of L-beta-aspartyl-L-glutamic acid, were particularly reduced in female APP/PS1 mice (A). B) 1-Methyladenosine, was more abundant in the hippocampus of female APP/PS1 mice compared to their WT female littermates (B). Significant Genotype X Treatment interactions were also found for N-acetyl-(L)-arginine (F (1, 34) =12.07, p=0.001), whose levels were significantly lower in PBS-treated APP/PS1 females compared to PBStreated WT females (C), and for the hydrophobic tetrapeptide Asp-Phe-Thr-Thr (F (1, 34) 
